title: Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia.
abstract: Decreased plasma high-density-lipoprotein (HDL) cholesterol and apolipoprotein A-I levels have been associated with premature coronary artery disease. We identified a PstI restriction-endonuclease site flanking the human apolipoprotein A-I gene at its 3' end that is polymorphic. The absence and presence of this site, as determined by genomic blotting analysis of PstI-digested chromosomal DNA with the use of an apolipoprotein A-I gene probe, were associated with 3.3-kb and 2.2-kb hybridization bands, respectively. The 3.3-kb band appeared in 4.1 percent of 123 randomly selected control subjects and in 3.3 percent of 30 subjects with no angiographic evidence of coronary artery disease. In contrast, among 88 patients who had severe coronary disease before the age of 60, as documented by angiography, the 3.3-kb band occurred in 32 percent (P less than 0.0001). It was also found in 8 of 12 index cases (P less than 0.0001) of kindreds with familial hypoalphalipoproteinemia. In the two patient groups, the allele frequencies of the site that produced the 3.3-kb band were 17 and 42 percent, respectively, as compared with an allele frequency of only 2 percent in the control populations. Within kindreds with familial hypoalphalipoproteinemia and among first-degree relatives of patients with coronary artery disease, the 3.3-kb band was associated with decreased HDL cholesterol levels. Among all patients with coronary artery disease, 58 percent had HDL cholesterol levels below the 10th percentile of normal values; however, this frequency increased to 73 percent when patients with the 3.3-kb band were considered. These findings indicate that the polymorphism in the region between the apolipoprotein A-I and apolipoprotein C-III genes may be a useful marker for the risk of premature coronary artery disease and familial hypoalphalipoproteinemia.
authors.forename: J M
authors.initials: JM
authors.lastname: Ordovas
authors.forename: E J
authors.initials: EJ
authors.lastname: Schaefer
authors.forename: D
authors.initials: D
authors.lastname: Salem
authors.forename: R H
authors.initials: RH
authors.lastname: Ward
authors.forename: C J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: C
authors.initials: C
authors.lastname: Vergani
authors.forename: P W
authors.initials: PW
authors.lastname: Wilson
authors.forename: S K
authors.initials: SK
authors.lastname: Karathanasis
mesh_terms: D000367:Age Factors; D000483:Alleles; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000235:genetics*; D002784:Cholesterol / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL; D003327:Coronary Disease / Q000235:genetics*; D004247:DNA / Q000032:analysis; D005260:Female; D005787:Gene Frequency; D006801:Humans; D007525:Isoelectric Focusing; D008075:Lipoproteins, HDL / Q000097:blood / Q000172:deficiency / Q000235:genetics*; D008079:Lipoproteins, VLDL / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009693:Nucleic Acid Hybridization; D011110:Polymorphism, Genetic
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL; D004247:DNA; D002784:Cholesterol